Jivi
damoctocog alfa pegol · Bayer AG
AUTHORISED IN THE EUWhat Jivi is used for
Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Jivi
- Active substance
- damoctocog alfa pegol
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- Bayer AG
- Authorised in the EU since
- 2018
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jivi used for?
Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).
What is the active substance in Jivi?
Jivi contains damoctocog alfa pegol.
Who makes Jivi?
The EU marketing authorisation holder is Bayer AG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU